Purpose: Nuclear grade is an important indicator of the biological behaviour of ductal carcinoma in situ (DCIS). De-escalation of treatment has been suggested for low-grade DCIS. Our aim is to estimate the relative rate of progression of DCIS by nuclear grade by analysing the distribution of nuclear grade by detection at initial or subsequent screening.

Methods: We asked International Cancer Screening Network sites to complete, based on their screening and clinical databases, an aggregated data file on DCIS detection, diagnosis and treatment.

Results: Eleven screening programs reported 5068 screen-detected pure DCIS in nearly 7 million screening tests in women 50-69 years of age. For all programs combined, low-grade DCIS were 20.1% (range 11.4-31.8%) of graded DCIS, intermediate grade 31.0% and high grade 48.9%. Detection rates decreased more steeply from initial to subsequent screening in low compared to high-grade DCIS: the ratios of subsequent to initial detection rates were 0.39 for low grade, 0.51 for intermediate grade, and 0.75 for high grade (p < 0.001).

Conclusions: These results suggest that the duration of the preclinical detectable phase is longer for low than for high-grade DCIS. The findings from this large multi-centre, international study emphasize that the management of low-grade DCIS should be carefully scrutinized in order to minimize overtreatment of screen-detected slow-growing or indolent lesions. The high variation by site in the proportion of low grade suggests that further pathology standardization and training would be beneficial.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05333-6DOI Listing

Publication Analysis

Top Keywords

nuclear grade
12
ductal carcinoma
8
carcinoma situ
8
grade
8
dcis
8
low-grade dcis
8
initial subsequent
8
intermediate grade
8
high grade
8
detection rates
8

Similar Publications

Primary Pulmonary MALT Lymphoma on 18F-FDG and 68Ga-FAPI PET/CT.

Clin Nucl Med

January 2025

From the Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Primary pulmonary mucosa-associated lymphoid tissue lymphoma is extremely rare. We present the 18F-FDG and 68Ga-FAPI PET/CT findings in a 56-year-old woman with pathologically confirmed primary pulmonary mucosa-associated lymphoid tissue lymphoma. 68Ga-FAPI PET/CT showed a higher uptake value than 18F-FDG PET/CT in the pulmonary lesion.

View Article and Find Full Text PDF

Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs (VIPomas) not responsive to any other therapies who achieved symptomatic control and a significant decrease in serum VIP levels with PRRT during their hospital stay. Two patients with VIPomas were admitted to the hospital with multiple prior hospital admissions after going through multiple lines of therapy.

View Article and Find Full Text PDF

We analyzed data for a cohort of 111 patients with EMBARK-like biochemical recurrence (BCR) of prostate cancer (prostate-specific antigen [PSA] doubling time ≤9 mo, PSA ≥1 ng/ml) after radical prostatectomy and localized oligorecurrence on prostate-specific membrane antigen (PSMA)-based imaging. All patients underwent PSMA-radioguided surgery (RGS). At PSMA-RGS, the median PSA was 1.

View Article and Find Full Text PDF

Introduction: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety and efficacy, prior to expansion into a randomized phase. Here we report those results.

View Article and Find Full Text PDF

Objectives: To assess the prognostic value of Fluorine 18-labeled fluorodeoxyglucose [F]FDG, gallium 68-labeled fibroblast-activation protein inhibitor-04 [Ga]Ga-FAPI-04, C-acetate in hepatocellular carcinoma (HCC) and evaluate the potential usefulness and advantages of different combinations for accurate diagnosis.

Materials And Methods: Thirty-six patients with suspected hepatic masses were prospectively enrolled from May 2021 to September 2022 and underwent [F]FDG, [Ga]Ga-FAPI-04, and C-acetate PET/CT scans before surgery. PET/CT results and histopathologic examinations were independently interpreted by two radiologists and pathologists, respectively.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!